​

10x Genomics (TXG) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TXG Stock Forecast

10x Genomics stock forecast is as follows: an average price target of $31.75 (represents a 115.69% upside from TXG’s last price of $14.72) and a rating consensus of 'Hold', based on 9 wall street analysts offering a 1-year stock forecast.

TXG Price Target

The average price target for 10x Genomics (TXG) is $31.75 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $24.00. This represents a potential 115.69% upside from TXG's last price of $14.72.

TXG Analyst Ratings

Hold

According to 9 Wall Street analysts, 10x Genomics's rating consensus is 'Hold'. The analyst rating breakdown for TXG stock is 0 'Strong Buy' (0.00%), 3 'Buy' (33.33%), 5 'Hold' (55.56%), 1 'Sell' (11.11%), and 0 'Strong Sell' (0.00%).

10x Genomics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2024Tejas SavantMorgan Stanley$46.00$19.65134.10%212.50%
Jul 23, 2024Kyle MiksonCanaccord Genuity$32.00$18.1176.70%117.39%
Jul 10, 2024Justin BowersDeutsche Bank$25.00$18.2536.99%69.84%
Jun 28, 2024Luke SergottBarclays$24.00$19.8520.91%63.04%
Jun 03, 2024Tycho PetersonJefferies$24.00$22.427.05%63.04%
May 01, 2024Luke SergottBarclays$36.00$29.2822.95%144.57%
Apr 10, 2024Luke SergottBarclays$45.00$37.3720.42%205.71%
Dec 14, 2022Deutsche Bank$50.00$35.2142.01%239.67%

The latest 10x Genomics stock forecast, released on Aug 13, 2024 by Tejas Savant from Morgan Stanley, set a price target of $46.00, which represents a 134.10% increase from the stock price at the time of the forecast ($19.65), and a 212.50% increase from TXG last price ($14.72).

10x Genomics Price Target by Period

1M3M12M
# Anlaysts--7
Avg Price Target--$33.14
Last Closing Price$14.72$14.72$14.72
Upside/Downside-100.00%-100.00%125.14%

In the current month, the average price target of 10x Genomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 10x Genomics's last price of $14.72. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024UBSNeutralNeutralHold
Oct 30, 2024Goldman SachsSellSellHold
Oct 30, 2024CitigroupBuyBuyHold
Oct 16, 2024Cowen & Co.HoldHoldHold
Oct 10, 2024UBSBuyBuyHold
Oct 10, 2024StephensUnderperformUnderperformHold
Sep 03, 2024UBSBuyBuyHold
Aug 13, 2024UBSBuyBuyHold
Aug 13, 2024JefferiesUnderperformUnderperformHold
Jul 22, 2024JefferiesHoldBuyUpgrade
Jul 10, 2024Deutsche BankBuyHoldDowngrade
Jun 28, 2024BarclaysOverweightOverweightHold
Jun 27, 2024Wolfe ResearchPeer PerformDowngrade
Jun 25, 2024GuggenheimNeutralDowngrade
Jun 03, 2024JefferiesHoldInitialise
May 01, 2024Cowen & Co.HoldDowngrade
May 01, 2024BarclaysOverweightOverweightHold
Mar 26, 2024CFRABuyUpgrade
Dec 12, 2023Bank of America SecuritiesNeutralUpgrade
Dec 14, 2022Deutsche BankBuyInitialise
Aug 18, 2022Goldman SachsNeutralDowngrade

10x Genomics's last stock rating was published by UBS on Oct 30, 2024. The company gave TXG a "Neutral" rating, the same as its previous rate.

10x Genomics Financial Forecast

10x Genomics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$153.64M$146.82M$134.28M$156.23M$131.07M$114.61M$114.50M$143.53M$125.30M$115.84M$105.82M$112.22M$71.82M$42.91M$71.91M$75.29M$61.21M
Avg Forecast$192.04M$182.47M$171.91M$163.85M$172.80M$161.68M$152.40M$143.13M$153.40M$156.89M$150.08M$142.24M$182.73M$151.30M$139.97M$128.82M$148.17M$128.96M$115.70M$113.25M$148.53M$122.56M$112.85M$102.51M$100.40M$61.19M$32.56M$73.42M$70.00M$54.90M
High Forecast$201.90M$191.84M$180.73M$172.26M$181.68M$169.99M$160.23M$153.06M$155.00M$159.89M$150.08M$142.24M$182.80M$155.34M$147.16M$135.43M$155.78M$128.96M$115.70M$113.25M$148.53M$122.56M$112.85M$102.51M$100.40M$61.19M$32.56M$73.42M$70.00M$54.90M
Low Forecast$186.78M$177.48M$167.20M$159.36M$168.07M$157.26M$148.23M$137.61M$151.39M$153.90M$150.08M$142.24M$182.60M$142.24M$136.14M$125.29M$144.11M$128.96M$115.70M$113.25M$148.53M$122.56M$112.85M$102.51M$100.40M$61.19M$32.56M$73.42M$70.00M$54.90M
# Analysts64464379115113109988889999999988
Surprise %-------------1.02%1.05%1.04%1.05%1.02%0.99%1.01%0.97%1.02%1.03%1.03%1.12%1.17%1.32%0.98%1.08%1.11%

10x Genomics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $182.73M, with a low forecast of $182.60M, and a high forecast of $182.80M. TXG's average Quarter revenue forecast represents a 18.93% increase compared to the company's last Quarter revenue of $153.64M (Sep 23).

10x Genomics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379115113109988889999999988
EBITDA-------------$-94.80M$-63.36M$-49.63M$-16.29M$-39.92M$-63.72M$-41.57M$-8.45M$-9.15M$-2.56M$-4.43M$-402.89M$-59.99M$-34.97M$-15.92M$-3.19M$-6.85M
Avg Forecast$-65.88M$-62.60M$-58.98M$-56.21M$-59.29M$-55.47M$-52.29M$-49.11M$-52.63M$-53.83M$-51.49M$-44.78M$-62.69M$-51.91M$-48.02M$-40.71M$-6.20M$-27.37M$-24.55M$-32.18M$-31.52M$-26.01M$-23.95M$-6.35M$-21.31M$-12.98M$-6.91M$-10.94M$-14.85M$-5.13M
High Forecast$-64.08M$-60.89M$-57.36M$-54.67M$-57.66M$-53.95M$-50.85M$-47.21M$-51.94M$-52.80M$-51.49M$-35.82M$-62.65M$-48.80M$-46.71M$-32.57M$-4.96M$-27.37M$-24.55M$-25.74M$-31.52M$-26.01M$-23.95M$-5.08M$-21.31M$-12.98M$-6.91M$-8.75M$-14.85M$-4.11M
Low Forecast$-69.27M$-65.82M$-62.01M$-59.10M$-62.33M$-58.32M$-54.97M$-52.51M$-53.18M$-54.85M$-51.49M$-53.73M$-62.72M$-53.30M$-50.49M$-48.85M$-7.44M$-27.37M$-24.55M$-38.62M$-31.52M$-26.01M$-23.95M$-7.61M$-21.31M$-12.98M$-6.91M$-13.12M$-14.85M$-6.16M
Surprise %-------------1.83%1.32%1.22%2.63%1.46%2.60%1.29%0.27%0.35%0.11%0.70%18.91%4.62%5.06%1.46%0.21%1.33%

undefined analysts predict TXG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 10x Genomics's previous annual EBITDA (undefined) of $NaN.

10x Genomics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379115113109988889999999988
Net Income-------------$-92.99M$-62.41M$-50.75M$-17.21M$-41.91M$-64.46M$-42.41M$-18.45M$-17.17M$-11.05M$-11.55M$-415.57M$-65.85M$-40.17M$-21.14M$-7.13M$-9.60M
Avg Forecast$-28.60M$-31.77M$-40.04M$-46.64M$-29.24M$-33.10M$-41.07M$-47.27M$-37.15M$-39.68M$-57.83M$-45.69M$-42.17M$-55.59M$-48.24M$-41.54M$-13.53M$-56.05M$-46.56M$-32.84M$-10.37M$-22.69M$-31.25M$-16.56M$-22.79M$-36.59M$-59.79M$-14.52M$-15.68M$-7.20M
High Forecast$-27.58M$-30.64M$-38.62M$-44.98M$-28.20M$-31.92M$-39.61M$-38.92M$-7.69M$-38.27M$-55.78M$-36.55M$-25.77M$-38.67M$-46.52M$-33.23M$-10.82M$-56.05M$-46.56M$-26.27M$-10.37M$-22.69M$-31.25M$-13.25M$-22.79M$-36.59M$-59.79M$-11.62M$-15.68M$-5.76M
Low Forecast$-30.50M$-33.90M$-42.72M$-49.75M$-31.19M$-35.31M$-43.82M$-58.39M$-51.24M$-42.33M$-61.69M$-54.83M$-57.40M$-70.09M$-51.46M$-49.84M$-16.24M$-56.05M$-46.56M$-39.40M$-10.37M$-22.69M$-31.25M$-19.87M$-22.79M$-36.59M$-59.79M$-17.43M$-15.68M$-8.64M
Surprise %-------------1.67%1.29%1.22%1.27%0.75%1.38%1.29%1.78%0.76%0.35%0.70%18.24%1.80%0.67%1.46%0.45%1.33%

10x Genomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TXG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

10x Genomics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379115113109988889999999988
SG&A-------------$82.42M$91.51M$83.28M$78.89M$73.40M$79.34M$66.67M$69.88M$62.08M$68.70M$56.90M$55.97M$51.55M$44.42M$50.39M$38.76M$32.61M
Avg Forecast$110.10M$104.62M$98.56M$93.94M$99.08M$92.70M$87.38M$82.06M$87.95M$89.96M$86.05M$71.83M$104.77M$86.75M$80.25M$65.30M$51.24M$73.84M$66.25M$51.62M$85.04M$70.17M$64.61M$81.56M$57.48M$35.03M$18.64M$34.61M$40.08M$24.46M
High Forecast$115.76M$109.99M$103.62M$98.77M$104.16M$97.46M$91.87M$87.76M$88.87M$91.67M$86.05M$86.19M$104.81M$89.07M$84.37M$78.36M$61.49M$73.84M$66.25M$61.94M$85.04M$70.17M$64.61M$97.87M$57.48M$35.03M$18.64M$41.53M$40.08M$29.35M
Low Forecast$107.09M$101.76M$95.86M$91.37M$96.36M$90.16M$84.99M$78.90M$86.80M$88.24M$86.05M$57.46M$104.70M$81.55M$78.06M$52.24M$40.99M$73.84M$66.25M$41.30M$85.04M$70.17M$64.61M$65.25M$57.48M$35.03M$18.64M$27.69M$40.08M$19.57M
Surprise %-------------0.95%1.14%1.28%1.54%0.99%1.20%1.29%0.82%0.88%1.06%0.70%0.97%1.47%2.38%1.46%0.97%1.33%

10x Genomics's average Quarter SG&A projection for Dec 23 is $104.77M, based on 3 Wall Street analysts, with a range of $104.70M to $104.81M. The forecast indicates a 27.12% rise compared to TXG last annual SG&A of $82.42M (Sep 23).

10x Genomics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379115113109988889999999988
EPS-------------$-0.79$-0.53$-0.44$-0.15$-0.37$-0.57$-0.38$-0.16$-0.15$-0.10$-0.11$-3.87$-0.65$-0.41$-0.22$-0.07$-0.33
Avg Forecast$-0.24$-0.26$-0.33$-0.39$-0.24$-0.27$-0.34$-0.39$-0.31$-0.33$-0.48$-0.50$-0.35$-0.46$-0.40$-0.37$-0.28$-0.47$-0.39$-0.34$-0.09$-0.19$-0.26$-0.27$-0.19$-0.30$-0.50$-0.13$-0.13$-0.13
High Forecast$-0.23$-0.25$-0.32$-0.37$-0.23$-0.26$-0.33$-0.32$-0.06$-0.32$-0.46$-0.48$-0.21$-0.32$-0.39$-0.36$-0.27$-0.47$-0.39$-0.34$-0.09$-0.19$-0.26$-0.27$-0.19$-0.30$-0.50$-0.13$-0.13$-0.13
Low Forecast$-0.25$-0.28$-0.35$-0.41$-0.26$-0.29$-0.36$-0.48$-0.42$-0.35$-0.51$-0.53$-0.48$-0.58$-0.43$-0.40$-0.30$-0.47$-0.39$-0.34$-0.09$-0.19$-0.26$-0.27$-0.19$-0.30$-0.50$-0.13$-0.13$-0.13
Surprise %-------------1.72%1.33%1.18%0.54%0.79%1.47%1.13%1.85%0.79%0.38%0.40%20.39%2.13%0.82%1.66%0.54%2.63%

According to undefined Wall Street analysts, 10x Genomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TXG previous annual EPS of $NaN (undefined).

10x Genomics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
FATEFate Therapeutics$1.88$5.00165.96%Buy
TXG10x Genomics$14.72$31.75115.69%Hold
BEAMBeam Therapeutics$28.58$55.0092.44%Buy
GHGuardant Health$34.84$40.6016.53%Buy
TWSTTwist Bioscience$48.40$46.00-4.96%Buy
VCYTVeracyte$42.24$35.00-17.14%Buy

TXG Forecast FAQ

Is 10x Genomics a good buy?

No, according to 9 Wall Street analysts, 10x Genomics (TXG) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 33.33% of TXG's total ratings.

What is TXG's price target?

10x Genomics (TXG) average price target is $31.75 with a range of $24 to $46, implying a 115.69% from its last price of $14.72. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will 10x Genomics stock go up soon?

According to Wall Street analysts' prediction for TXG stock, the company can go up by 115.69% (from the last price of $14.72 to the average price target of $31.75), up by 212.50% based on the highest stock price target, and up by 63.04% based on the lowest stock price target.

Can 10x Genomics stock reach $20?

TXG's average twelve months analyst stock price target of $31.75 supports the claim that 10x Genomics can reach $20 in the near future.

What are 10x Genomics's analysts' financial forecasts?

10x Genomics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $630.02M (high $664.95M, low $611.17M), average EBITDA is $-216M (high $-210M, low $-228M), average net income is $-151M (high $-139M, low $-169M), average SG&A $361.22M (high $381.25M, low $350.42M), and average EPS is $-1.248 (high $-1.148, low $-1.397). TXG's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $710.26M (high $746.73M, low $690.82M), average EBITDA is $-244M (high $-237M, low $-256M), average net income is $-147M (high $-142M, low $-157M), average SG&A $407.23M (high $428.14M, low $396.08M), and average EPS is $-1.218 (high $-1.175, low $-1.299).

Did the TXG's actual financial results beat the analysts' financial forecasts?

Based on 10x Genomics's last annual report (Dec 2022), the company's revenue was $516.41M, beating the average analysts forecast of $506.09M by 2.04%. Apple's EBITDA was $-161M, beating the average prediction of $-90.3M by 78.84%. The company's net income was $-166M, beating the average estimation of $-149M by 11.43%. Apple's SG&A was $298.3M, beating the average forecast of $242.95M by 22.78%. Lastly, the company's EPS was $-1.46, missing the average prediction of $-1.468 by -0.58%. In terms of the last quarterly report (Sep 2023), 10x Genomics's revenue was $153.64M, beating the average analysts' forecast of $151.3M by 1.55%. The company's EBITDA was $-94.795M, beating the average prediction of $-51.909M by 82.62%. 10x Genomics's net income was $-92.986M, beating the average estimation of $-55.587M by 67.28%. The company's SG&A was $82.42M, missing the average forecast of $86.75M by -5.00%. Lastly, the company's EPS was $-0.79, beating the average prediction of $-0.46 by 71.59%